09:02 AM EST, 11/05/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) reported a Q3 net loss Wednesday of $0.85 per diluted share, widening from a loss of $0.54 a year earlier.

Three analysts polled by FactSet expected a loss of $0.73.

Revenue for the quarter ended Sept. 30 was $966,000, compared with $10.5 million a year earlier.

Analysts surveyed by FactSet expected $3.5 million.

The company reported it had $204 million in cash, cash equivalents, and marketable securities as of Sept. 30, sufficient to fund operations into Q4 2027.

Shares of the company were down over 6% in recent Wednesday premarket activity.